Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer

International Journal of Pharmaceutics
Barbara ZiembaBarbara Klajnert-Maculewicz

Abstract

Since the first dendrimers were synthesized, scientists around the world have studied their properties and potential applications. Cationic dendrimers are characterized by significant toxicity due to their interactions with cells components. The replacement of all cationic surface groups by neutral ones and therefore diminishing positive charge reduces the toxicity but may also lead to loss of dendrimers' desirable properties and restrict their biomedical applications. We have compared the cytotoxicity, as well as proapoptotic and antiproliferative activity of unmodified fourth generation PPI dendrimer (PPI-G4) and dendrimers modified with maltose (Mal) or maltotriose (Mal-III) - for full (dense shell - DS) or partial (open shell - OS) surface modifications. We have proved that among glycodendrimers, the OS-Mal PPI-G4 dendrimer is the most toxic, whereas DS-Mal-III molecule shows relatively weak or even no effect. We have also confirmed that OS dendrimers, both maltotriose and maltose modified, not only reduce cancer cells viability by inducing apoptosis but also inhibit their proliferation. The use of dendrimers as an active substance, which may be a drug per se is one of the most exciting and clinically important applications...Continue Reading

References

Oct 26, 2000·Nature·M O Hengartner
Jan 29, 2003·International Journal of Pharmaceutics·R JevprasesphantA D'Emanuele
Apr 25, 2003·International Journal of Pharmaceutics·D BhadraN K Jain
Jan 23, 2004·Chemical Society Reviews·Ulrik Boas, Peter M H Heegaard
Sep 14, 2004·Biomacromolecules·Dariusz M DomańskiGrzegorz Salamończyk
Sep 29, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Joon Sig ChoiJong-Sang Park
Apr 26, 2005·International Journal of Pharmaceutics·D BhadraN K Jain
Nov 30, 2006·The Journal of Pharmacy and Pharmacology·Hrushikesh B AgasheN K Jain
Aug 19, 2007·Pharmaceutical Research·Kelly M KitchensHamidreza Ghandehari
Nov 17, 2007·Biomacromolecules·Nathan A StaskoEkhson L Holmuhamedov
Nov 4, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Sonke Svenson
Apr 23, 2009·The Journal of Physical Chemistry. B·E FroehlichH A Tajmir-Riahi
Jun 9, 2009·Journal of Biophotonics·Msaukiranji MkandawireJörg Opitz
Sep 26, 2009·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Sourav Prasanna MukherjeeHugh J Byrne
Apr 13, 2010·International Journal of Pharmaceutics·Umesh GuptaN K Jain
Aug 26, 2010·Toxicology and Applied Pharmacology·Sourav Prasanna MukherjeeHugh J Byrne
Dec 31, 2010·Colloids and Surfaces. B, Biointerfaces·Elzbieta Pedziwiatr-WerbickaMaria Bryszewska
Jan 5, 2011·Biomacromolecules·E FroehlichH A Tajmir-Riahi
Oct 7, 2011·Journal of Biomedical Materials Research. Part a·Barbara ZiembaBarbara Klajnert
Nov 17, 2011·Cellular & Molecular Biology Letters·Barbara ZiembaBarbara Klajnert
Mar 1, 2012·Journal of Physiology and Biochemistry·Karol CiepluchWiesława Agnieszka Fogel
Mar 14, 2012·Colloids and Surfaces. B, Biointerfaces·Michal CiolkowskiMaria Bryszewska
May 19, 2012·Biopolymers·Barbara ZiembaBarbara Klajnert
May 25, 2012·Journal of Biomedical Materials Research. Part a·Barbara ZiembaBarbara Klajnert
Sep 15, 2012·Experimental and Therapeutic Medicine·Hui WangShan-Kai Yin
Sep 22, 2012·Biochemical and Biophysical Research Communications·Joanna DrzewińskaBarbara Klajnert
Jan 12, 2013·Journal of Fluorescence·A SzulcB Klajnert
Apr 19, 2013·Journal of Drug Targeting·Udita AgrawalN K Jain

❮ Previous
Next ❯

Citations

Mar 19, 2016·International Journal of Biological Macromolecules·Ida Franiak-PietrygaMaciej Borowiec
Oct 25, 2016·International Journal of Pharmaceutics·Aleksandra SzulcBarbara Klajnert-Maculewicz
Apr 18, 2017·Biomacromolecules·Maciej StudzianBarbara Klajnert-Maculewicz
Jul 30, 2015·Biomaterials Science·Jason BugnoSeungpyo Hong
Nov 19, 2019·Anti-cancer Agents in Medicinal Chemistry·Barbara ZiembaIda Franiak-Pietryga
Jul 2, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ignacio Rodriguez-IzquierdoMaria Angeles Muñoz-Fernández
Nov 15, 2020·Drug and Chemical Toxicology·Ida Franiak-PietrygaMaciej Borowiec
Feb 1, 2020·Current Medicinal Chemistry·Elzbieta Pedziwiatr-WerbickaMaria Bryszewska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis